Lidings Intellectual Property practice lawyers have set a precedent in a dispute concerning patent extension.

Best Lawyers, an international legal directory annually identifying the most prominent lawyers around the world by analyzing their professional skills and achievements during the year, once again lists Lidings’ experts among the best lawyers in Russia.

Lawyers of the Lidings Intellectual Property practice have successfully represented interests of the Russian "Miloserdie" (eng.:Mercy) aid service in a trademark protection case. The work was done pro bono.

April 27th, 2021 annual conference Pharmaceuticals – 2021: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.

Partner and Head of the Lidings’ Intellectual Property practice Boris Malakhov will take part in an annual conference entitled Intellectual Property - 2021 organized by Pravo.ru. The conference will take place on 15th April 2021 in Marriott Royal Aurora.

March 11, 2021 Pravo.ru-300 released its individual rating of lawyers. Based on the new rating Lidings managing partner Andrey Zelenin, partners Stepan Guzey and Alexander Popleyuk take top positions in key practice areas.

Since 1 March 2021, the Pharmaceutical Register of the Eurasian Patent Office (EAPO) is available on the official website of the Eurasian Patent Office. The Register contains information on Eurasian patents protecting active substances of drugs.

The rating particularly states that Andrey is “well versed in all aspects of intellectual property and can hammer out favourable outcomes in difficult disputes in the life sciences, fast-moving consumer goods and high-technology spheres” and Boris is “a trusted adviser to numerous pharmaceutical companies on both the patent and trademark sides, and has further know-how in advertising and data protection.

Lidings’ managing partner Andrey Zelenin heading the firm’s Pharmaceuticals and Healthcare industry practice and partner Boris Malakhov, Head of the Intellectual Property practice of the firm, run a special webinar on the key market developments in the healthcare and life sciences sector in Russia.

On January 5, 2021 the Decree of the Government of the Russian Federation No. 3718-r dated December 31, 2020 (the Decree) was published. In accordance with the Decree, Pharmasintez JSC, a Russian generic company, has been granted a 1-year compulsory license to use the inventions of the US companies Gilead Sciences Inc. and Gilead Pharmasset LLC protecting Remdesivir subject to a “fair compensation”¹.